1). Marcé n R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, malignancy and infection. Drugs. 2009; 69:2227–43.
2). Carpenter CB. Improving the success of organ transplantation. N Engl J Med. 2000; 342:647–8.
Article
3). Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 342:605–12.
Article
4). Wimmer CD, Rentsch M, Crispin A, Illner WD, Arbogast H, Graeb C, et al. The janus face of immunosuppression: de novo malignancy after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int. 2007; 71:1271–8.
5). Vegso G, Tó th M, Hí dvé gi M, Toronyi E, Langer RM, Dinya E, et al. Malignancies after renal transplantation during 33 years at a single center. Pathol Oncol Res. 2007; 13:63–9.
6). Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther. 2000; 7:147–56.
Article
7). Zeier M, Hartschuh W, Wiesel M, Lehnert T, Ritz E. Malignancy after renal transplantation. Am J Kidney Dis. 2002; 39:E5.
Article
8). Penn I. The occurrence of cancer in immune deficiencies. Curr Probl Cancer. 1982; 6:1–64.
Article
9). Fischereder M. Cancer in patients on dialysis and after renal transplantation. Nephrol Dial Transplant. 2008; 23:2457–60.
Article
10). Swann PF, Waters TR, Moulton DC, Xu YZ, Zheng Q, Edwards M, et al. Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science. 1996; 273:1109–11.
Article
11). Boratyń ska M, Watorek E, Falkiewicz K, Banasik M. Increased plasma TGF-beta 1 level in patient with salivary gland carcinoma after renal transplantation. Ann Transplant. 2005; 10:16–9.
12). Guba M, Graeb C, Jauch KW, Geissler EK. Pro- and anticancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004; 77:1777–82.
Article
13). Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. Nephrol Dial Transplant. 2007; 22(Suppl 1):i4–10.
Article
14). Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004; 4:905–13.
Article
15). Ro H, Kim SM, Kim KW, Hwang YH, Yang JS, Oh KH, et al. Malignancy after kidney transplantation. J Korean Soc Transplant. 2006; 20:187–92. (노한, 김선문, 김기원, 황영환, 양재석, 오국환, 등. 신이식 후 발생한 악성종양: 단일기관에서의 37년 발생양상 분석. 대한이식학회지 2006;20: 187–92.).
16). Kim HS, Seo YM, Park UJ, Kim HT, Cho WH, Hwang EA, et al. Crude incidence rate of malignancy after kidney transplantation. J Korean Soc Transplant. 2010; 24:182–6. (김효선, 서영민, 박의준, 김형태, 조원현, 황은아, 등. 면역억제제 노출기간을 고려한 신이식 후 악성종양의 조발생률. 대한이식학회지 2010;24: 182–6.).
Article
17). Hoshida Y, Aozasa K. Malignancies in organ transplant recipients. Pathol Int. 2004; 54:649–58.
Article
18). Berber I, Altaca G, Aydin C, Dural A, Kara VM, Yigit B, et al. Kaposi's sarcoma in renal transplant patients: predisposing factors and prognosis. Transplant Proc. 2005; 37:967–8.
Article
19). Sheil AG, Disney AP, Mathew TH, Amiss N. De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation. Transplant Proc. 1993; 25(1 Pt 2):1383–4.
20). Smith JM, Rudser K, Gillen D, Kestenbaum B, Seliger S, Weiss N, et al. Risk of lymphoma after renal transplantation varies with time: an analysis of the United States Renal Data System. Transplantation. 2006; 81:175–80.
21). Utada M, Ohno Y, Hori M, Soda M. Incidence of multiple primary cancers and interval between first and second primary cancers. Cancer Sci. 2014; 105:890–6.
Article
22). Tremblay F, Fernandes M, Habbab F, de BEMD, Loertscher R, Meterissian S. Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol. 2002; 9:785–8.
Article
23). Bustami RT, Ojo AO, Wolfe RA, Merion RM, Bennett WM, McDiarmid SV, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant. 2004; 4:87–93.
Article
24). Bang BK. Malignancy in renal transplant recipients. Korean J Nephrol. 2006; 25:S497–503.